메뉴 건너뛰기




Volumn 3, Issue 5, 2003, Pages 375-382

Antiangiogenesis and radiotherapy: What is the role of combined modality treatment?

Author keywords

Angiogenesis; Antiangiogenic; Antivascular treatment; Growth delay; Radiotherapy; TCD50

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; COMBRETASTATIN A4; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; N ACETYLCHOLINOL O PHOSPHATE; N ACETYLCOLCHINOL PHOSPHATE; NEUTRALIZING ANTIBODY; PHOSPHATE; PLATELET DERIVED GROWTH FACTOR; RECEPTOR ANTIBODY; SEMAXANIB; TETRATHIOMOLYBDIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2 ANTIBODY; VATALANIB;

EID: 0042386330     PISSN: 15680118     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568011033482305     Document Type: Review
Times cited : (3)

References (56)
  • 25
    • 0027970092 scopus 로고
    • O'Reilly, M. Cell, 1994, 79, 315-328.
    • (1994) Cell , vol.79 , pp. 315-328
    • O'Reilly, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.